Here we report on the expression of Siglec‐7 and Siglec‐9 and their ligands in TN and ER+ tumors and on Siglec‐7 and Siglec‐9 signalling induced by breast cancer cells to determine their potential as targets for future immunotherapy in breast cancer. This evidence concerns the gene SIGLEC9 and breast carcinoma.